MODAG GmbH
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.modag.net
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
- Conditions
- Healthy Volunteers
- Interventions
- Drug: anle138b (TEV-56286)
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- MODAG GmbH
- Target Recruit Count
- 54
- Registration Number
- NCT05532358
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Drug: anle138bDrug: Placebo
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- MODAG GmbH
- Target Recruit Count
- 70
- Registration Number
- NCT04685265
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: anle138bDrug: Placebo
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- MODAG GmbH
- Target Recruit Count
- 68
- Registration Number
- NCT04208152
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
News
Teva's Emrusolmin Receives FDA Fast Track Designation for Multiple System Atrophy Treatment
Teva Pharmaceuticals received FDA Fast Track designation for emrusolmin (TEV-56286), an investigational small molecule therapy targeting alpha-synuclein protein for Multiple System Atrophy treatment.
Multiple System Atrophy Pipeline Shows Promise with 22+ Therapies in Development as FDA Grants Fast Track Designations
The global Multiple System Atrophy (MSA) market is experiencing significant growth driven by emerging alpha-synuclein targeting therapies and advanced diagnostic technologies including high-resolution MRI and biomarker identification.